Prazosin

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C19H21N5O4
Molecular Weight
383.4 g/mol
PubChem CID
4893
Aliases
Minipress

Pharmacological Mechanism

Short-acting selective α1-adrenergic blocker. BP lowering + BPH symptom relief. Off-label for PTSD-related nightmares + sleep disturbance (raised α1 tone in PTSD; prazosin softens hyperarousal during sleep).

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~44.8 µg/L)1×t½ (3h): 50% remaining (~22.4 µg/L)2×t½ (6h): 25% remaining (~11.2 µg/L)3×t½ (9h): 12.5% remaining (~5.6 µg/L)4×t½ (12h): 6.3% remaining (~2.8 µg/L)5×t½ (15h): 3.1% remaining (~1.4 µg/L)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
  • 0×t½0h100% (44.8 µg/L)
  • 1×t½3h50% (22.4 µg/L)
  • 2×t½6h25% (11.2 µg/L)
  • 3×t½9h12.5% (5.6 µg/L)
  • 4×t½12h6.3% (2.8 µg/L)
  • 5×t½15h3.1% (1.4 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.8h
Est. Peak (Cmax)44.8 µg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References